- Home
- FNWD vs CHRS Comparison
FNWD vs CHRS Comparison
Compare FNWD & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNWD
- CHRS
- Stock Information
- Founded
- FNWD 1994
- CHRS 2010
- Country
- FNWD United States
- CHRS United States
- Employees
- FNWD N/A
- CHRS N/A
- Industry
- FNWD Savings Institutions
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FNWD Finance
- CHRS Health Care
- Exchange
- FNWD Nasdaq
- CHRS Nasdaq
- Market Cap
- FNWD 137.3M
- CHRS 159.2M
- IPO Year
- FNWD N/A
- CHRS 2014
- Fundamental
- Price
- FNWD $31.85
- CHRS $1.71
- Analyst Decision
- FNWD Buy
- CHRS Strong Buy
- Analyst Count
- FNWD 1
- CHRS 4
- Target Price
- FNWD $34.00
- CHRS $4.51
- AVG Volume (30 Days)
- FNWD 17.8K
- CHRS 1.2M
- Earning Date
- FNWD 10-23-2025
- CHRS 11-05-2025
- Dividend Yield
- FNWD 1.51%
- CHRS N/A
- EPS Growth
- FNWD N/A
- CHRS N/A
- EPS
- FNWD 1.24
- CHRS 1.55
- Revenue
- FNWD $63,780,000.00
- CHRS $272,209,000.00
- Revenue This Year
- FNWD N/A
- CHRS N/A
- Revenue Next Year
- FNWD $7.77
- CHRS $109.48
- P/E Ratio
- FNWD $25.64
- CHRS $1.10
- Revenue Growth
- FNWD N/A
- CHRS 52.33
- 52 Week Low
- FNWD $26.12
- CHRS $0.66
- 52 Week High
- FNWD $33.50
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- FNWD 53.93
- CHRS 69.28
- Support Level
- FNWD $31.53
- CHRS $1.56
- Resistance Level
- FNWD $32.97
- CHRS $1.78
- Average True Range (ATR)
- FNWD 0.90
- CHRS 0.12
- MACD
- FNWD -0.18
- CHRS 0.00
- Stochastic Oscillator
- FNWD 18.48
- CHRS 81.71
About FNWD Finward Bancorp
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.